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Antipsychotic drugs can induce various undesirable adverse
motor reactions, such as extrapyramidal side effects (EPS).
A widely accepted pharmacodynamic mechanism
underlying EPS includes an increase in striatal D2-receptor
occupancy. However, less is known about the
pharmacokinetic background of EPS. The aim of this study
was to analyze in-vivo possible pharmacokinetic patterns
underlying biperiden-treated EPS in risperidone (RIS)-
medicated patients. A large therapeutic drug monitoring
database containing plasma concentrations of RIS and its
metabolite 9-hydroxyrisperidone (9-OH-RIS) of 2293 adult
inpatients and outpatients was analyzed. Two groups were
compared: a group receiving RIS (n= 772) and a group
comedicated with biperiden (n= 68). Plasma
concentrations, dose-adjusted plasma concentrations
(C/D) of RIS, 9-OH-RIS, and active moiety (AM)
(RIS+ 9-OH-RIS) as well as ratios of concentrations for
metabolite to parent drug (9-OH-RIS/RIS) were computed.
We compared the plasma concentrations of the different
compounds between the two groups considering the
prescription of biperiden as an indirect report of EPS. The
daily dosage of RIS did not differ between groups. No
differences were detected in case of plasma concentrations
and C/D of RIS and active metabolite between the groups.
However, plasma concentrations of the AM were
significantly higher in the comedicated group (P= 0.032)
and showed a trend in terms of the active metabolite 9-OH-
RIS (P= 0.053). Data indicate enhanced AM plasma
concentrations of RIS in patients comedicated with
biperiden as an EPS treatment. This might underscore an
association between higher plasma concentrations of the
AM and treatment-requiring EPS. Int Clin Psychopharmacol
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Introduction
Treatment with first-generation antipsychotics is con-
sistently associated with a variety of undesirable adverse
motor reactions, widely known as extrapyramidal side
effects (EPS). These symptoms include acute dystonia,
akathisia, and parkinsonism (Simpson et al., 1981; Tarsy,
1983; Haddad and Dursun, 2008) or tardive dyskinesia
(TD) after a prolonged antipsychotic treatment (Casey,
2004).
The development of atypical (or second-generation)
antipsychotics (SGA) led to high expectations in terms of
the improvement of the safety profile (Glazer, 2000;
Caroff et al., 2002; Gebhardt et al., 2006). Accordingly, the
original concept of atypical antipsychotics included the
lack of EPS, but this concept has been considerably
broadened to include aspects such as efficacy against
negative and cognitive symptoms, lack of prolactin
elevation, and efficacy in treatment-resistant patients
(Gründer et al., 2009). Unfortunately, EPS remains the
most serious problem in patients with schizophrenia,
even in the era of SGA. EPS can exert deleterious effects
on the clinical outcome, compliance, and quality of life
(Hammer and Haddad, 2007).
The pharmacological mechanism of EPS seems to be a
relative dopamine deficiency on the basis of a striatal
dopamine D2-receptor occupancy and a relative acet-
ylcholine excess (Ginovart and Kapur, 2012). Apart from
the EPS-inducing effect, the D2 antagonistic affinity has
been considered to be the main antipsychotic property of
first-generation antipsychotics. An increase in a hypo-
thetical threshold of striatal D2-receptor occupancy of
about 80% is associated with EPS (Farde et al., 1992).
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Gründer et al. (2009) proposed that the low incidence of
EPS, which characterizes atypical antipsychotics, can be
ascribed to the fact that the drugs leave dopaminergic
neurotransmission in extrapyramidal motor systems
intact.
Anticholinergic drugs including biperiden play a wide-
spread and established role in therapeutic strategies for
the acute management or the prevention of EPS
(McEvoy, 1983). In case of parkinsonism, dose adjust-
ment and anticholinergic drugs might be essential; in
constrast, in the management of TDs, anticholinergics
are not recommended. Tapering of prescribed antic-
holinergics and switch to SGAs may result in better
efficacy (Soares and Mcgrath, 2000).
Biperiden is a weak anticholinergic agent and the
mechanism of action is considered to be related to com-
petitive antagonism of acetylcholine at cholinergic
receptors in the corpus striatum, which then restores the
balance in acute episodes of extrapyramidal disturbances
sometimes encountered during treatment with anti-
psychotic agents. Despite its wide usage, the metabolic
pathway of biperiden remains unclear; evidence implies
an extensive hepatic extraction with the possible invol-
vement of CYP2D6 (Grimaldi et al., 1986). In terms of
pharmacokinetic interactions, studies have reported a low
pharmacokinetic interaction potential (Yisak et al., 1993,
Isawa et al., 1999), whereas one study suggests biperiden
as a competitive inhibitor of CYP2D6 (Ieiri et al., 2003).
Risperidone (RIS) is a SGA with selective antagonistic
properties at serotonin 5-HT2-receptors and dopamine
D2-receptors (Janssen et al., 1988). RIS has been used
effectively in the treatment of schizophrenia and a broad
spectrum of other psychiatric diseases over the past two
decades with a satisfactory safety profile (Leucht et al.,
1999). Nevertheless, a series of case reports have con-
gruently shown the EPS-inducing and particularly TD-
inducing effects of RIS, especially in therapeutic regi-
mens with multiple psychotropic drugs (Saran, 1998;
Hong et al., 1999). Other researchers have reported a
linear relationship between RIS dosage and the occur-
rence of EPS (Umbricht and Kane, 1996). The primary
pathway of RIS metabolism is a CYP2D6-catalyzed
9-hydroxylation and the main active metabolite is
9-hydroxyrisperidone (9-OH-RIS). In-vitro findings have
shown that CYP3A4 and CYP3A5 might also be involved
in the metabolism of RIS (Fang et al., 1999;
Yasui-Furukori et al., 2001; Xiang et al., 2010). Preclinical
studies indicated that 9-OH-RIS has ∼ 70% of the phar-
macological activity of RIS (Heykants et al., 1994).
Therefore, clinicians consider the combined concentration
of RIS and 9-OH-RIS [active moiety (AM)] as the most
relevant measure (Regenthal et al., 2005). According to
the Arbeitsgemeinschaft für Neuropsychopharmakologie
und Pharmakopsychiatrie (AGNP) consensus guideline, a
so-called therapeutic reference range is suggested to be
20–60 ng/ml for the AM (Hiemke et al., 2011).
Therapeutic drug monitoring (TDM) databases are a
valuable source for a better understanding of potential
pharmacokinetic interactions helping to minimize
adverse effects (Spina et al., 2001; Spina et al., 2016) by
revealing problematic drug combinations showing up in
elevated or decreased drug concentrations.
Here, we analyzed data from a TDM survey conducted
in patients whose antipsychotic treatment with RIS was
optimized individually using TDM. Considering the
individual prescription of biperiden as an indirect report
of existing EPS, we investigated differences between
patients under a combined treatment with RIS and
biperiden and patients without anticholinergics to further
investigate potential pharmacokinetic interactions as
enhanced active metabolite (9-OH-RIS) concentrations
in RIS-treated patients under concomitant medication
with biperiden have already been reported (Balant-
Gorgia et al., 1999). Furthermore, we aimed to elucidate
whether biperiden-medicated patients were character-
ized by higher plasma concentrations of RIS, 9-OH-RIS,
and AM reflecting a potentially higher dopamine D2-
receptor occupancy leading to a higher incidence of EPS.
We addressed the hypothesis that patients who were
medicated with biperiden had higher plasma concentra-
tions exceeding the hypothetical threshold for EPS of
striatal D2-receptor occupancy of about 80% at a higher
percentage than patients without anticholinergics.
Materials and methods
The study was carried out as a collaboration between
the Department of Psychiatry, Psychotherapy and
Psychosomatics of RWTH Aachen University Hospital,
Aachen, Germany, and the Department of Psychiatry
and Psychotherapy at the University of Regensburg,
Germany. A large TDM database as part of KONBEST,
a web-based laboratory information management system
for TDM laboratories (Haen, 2011) containing plasma
concentrations of RIS and 9-OH-RIS of 2293 patients,
was analyzed. Data collection was performed between
2006 and 2015 as part of the clinical routine in different
institutions of the AGATE, ‘Arbeitsgemeinschaft
Arzneimittelsicherheit bei psychischen Erkrankungen’, a
cooperation for drug safety in the treatment of psychiatric
diseases, (for details, see http://www.amuep-agate.de). The
database consists of 2293 samples from adult inpatients
and outpatients who had been treated with RIS for dif-
ferent reasons. Retrospective analysis of clinical data for
this study was carried out in accordance with the local
regulatory authority.
In this naturalistic database, patients were under medi-
cation with RIS. Patients under concomitant medication
with possible CYP2D6 inhibitory or CYP3A4 inhibitory
or inducing properties were excluded (Hiemke et al.,
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2011; US Food and Drug Administration, 2014). Samples
with missing data of RIS, its pharmacokinetic parameters,
or clinical response were also not included in the analysis.
In a minimal number of cases, missing BMI data were
detected and were consequently substituted by the
median values.
Quantification of risperidone and 9-OH-risperidone
Blood was asked to be drawn just before drug adminis-
tration (trough concentration) at steady state (>5 elim-
ination half-lives under the same drug dose). RIS and
9-OH-RIS concentrations were determined by high
performance liquid chromatography with ultraviolet
detection (Bader et al., 2005). The method was validated
according to Deutsche Industrie Norm 32645 described
in the guidelines of GTFCh (Society of Toxicology and
Forensic Chemistry) in consideration of International
Organization for Standardization 5725 (Paul et al., 2009),
FDA (US FDA) guidances (US Food and Drug
Administration, 2001), and International Conference on
Harmonization requirements (ICH expert working
group, 1996). The laboratory regularly runs internal
quality controls and participates in external quality
assessment schemes by INSTAND (Düsseldorf,
Germany; http://www.instandev.de).
Statistical analysis
The analysis included mainly the comparison of two
study groups: a group receiving RIS without cytochrome
enzyme influencing comedication (control group, R0) and
a group receiving RIS plus the anticholinergic agent
biperiden (RB). We compared the medians and the dis-
tributions of the plasma concentration of RIS, 9-OH-RIS,
and the AM (RIS+ 9-OH-RIS) between the groups.
Further comparisons included the plasma concentration
corrected by the daily dose, the so-called ‘concentration-
by-dose’, (C/D), and the ratios of 9-OH-RIS/RIS for
identification of the CYP2D6 metabolizer status. Both
were calculated in accordance with the AGNP consensus
guidelines (Hiemke et al., 2011). Histograms yielded
evidence of non-normally distributed data so that a
nonparametrical Mann–Whitney U-test and a median test
with a significance level of 0.05 was performed. In a
minimal number of cases, missing BMI data were
detected and were consequently substituted by the
median values. Statistical analysis was carried out using
IBM SPSS statistics, version 18.0 (IBM GmbH,
Ehningen, Germany).
Results
After exclusion of potentially confounding comedica-
tions, 840 out of 2293 patients fulfilled the inclusion
criteria. Data of these patients were included in the
analysis and were assigned to two groups: RB and R0.
The demographic data of these patients are summarized
in Table 1. The biperiden group included 68 patients,
whereas the control group included 772 patients.
The median plasma concentrations (ng/ml) of RIS,
9-OH-RIS, the AM (RIS+ 9-OH-RIS), as well as the
metabolic ratios (9-OH-RIS/RIS) are shown in Table 2.
Table 3 shows the dose-adjusted plasma concentrations,
C/D (ng/ml/mg), for RIS, 9-OH-RIS, and RIS+ 9-OH-
RIS for each of the two groups.
Because of the skewness of the distribution, we per-
formed comparisons on the basis of the Mann–Whitney
U-test. The median daily dosage of RIS (Table 1) did not
differ between the two groups (P= 0.095). Groups did
not differ in demographic characteristics (P= 0.667 for
age, P= 0.118 for sex, and P= 0.144 for BMI). The
comparison of the distribution of the plasma concentra-
tions of RIS, 9-OH-RIS, and the AM (RIS+ 9-OH-RIS)
between the two groups did not yield significant differ-
ences in the case of RIS (P= 0.108) and in the case of
9-OH-RIS (P= 0.053). However, in the case of the AM,
patients under concomitant anticholinergic medication
showed significantly higher values than the control group
(P= 0.032) (Fig. 1). This difference was not reflected in
the findings of the comparison of C/D values of AM
(P= 0.421). Differences in the C/D values in all other
cases and the ratios of concentrations 9-OH-RIS/RIS did
not reach statistical significance (P= 0.369 for C/D RIS,
P= 0.42 for 9-OH-RIS, and P= 0.706 for 9-OH-RIS/RIS,
respectively).
Discussion
In our naturalistic sample of RIS-medicated patients, we
considered the prescription of an anticholinergic treat-
ment with biperiden as an indication of treatment
because of EPS. We therefore sought pharmacokinetic
differences not just in terms of RIS metabolism reflecting
differences in the plasma concentrations of RIS, 9-OH-
Table 1 Patients’ demographic characteristics
Sex (%)
Group Number Age (years)
BMI
(kg/m2) Females Males
DD RIS [median
(range)] (mg/day)
RB 68 40.32 (18–74) 26.25 52.9 47.1 4.5 (1.00–10.00)
R0 772 41.25 (18–87) 27.04 43.1 56.9 4.0 (1.00–10.00)
DD, daily dose; RIS, risperidone.
Table 2 Median plasma concentrations (range) for risperidone and
9-hydroxyrisperidone in the study groups without (R0) and with
concomitant biperiden medication (RB)
Group RIS 9-OH-RIS RIS+9-OH-RIS
RB 5.65 (0.4–143.0) 18.3 (1.4–106.0)↑
a 27.0 (5.3–249.0)↑a
R0 4.25 (0.1–224.0) 17.0 (0.3–196.5) 23.9 (1.8–264.0)
RIS, risperidone; 9-OH-RIS, 9-hydroxyrisperidone.
aPlasma concentration values for active moiety in patients under concomitant
anticholinergic medication with biperiden were significantly higher than those in
the control group (P=0.032 for the Mann–Whitney U-test), whereas a trend was
detected in the case of 9-OH-RIS (P=0.053).
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RIS, and AM between the patients receiving biperiden
and patients without a concomitant anticholinergic
medication. Differences reached statistical significance in
case of plasma concentrations of the AM, whereas a trend
was detected for plasma concentrations of 9-OH-RIS;
patients with treatment requiring EPS showed higher
values in both cases. These findings validate results from
an older TDM study with significantly higher plasma
concentrations of 9-OH-RIS in biperiden-medicated
patients (Balant-Gorgia et al., 1999) as well as findings
from a study by Aichhorn et al. (2005) who found sig-
nificantly higher concentrations of total plasma con-
centrations (AM) in biperiden comedicated patients,
although the latter study additionally found significantly
higher concentrations of the parent compound in the
biperiden group.
There have been a series of studies assessing correlations
between pharmacokinetic parameters and EPS on the
basis of various scales. Because of the heterogeneity of
study samples and methods, evidence has been con-
flicting so far. In a group of chronic schizophrenic
patients, no correlation was reported between pharma-
cokinetic parameters of RIS and drug-induced adverse
reactions including extrapyramidal and anticholinergic
side effects (Mauri et al., 2001). This finding was repli-
cated by Riedel et al. (2005), who found no correlation
between EPS and plasma concentrations, although they
detected a significant role of higher RIS plasma con-
centrations after 2 weeks in predicting the incidence of
EPS. Similarly, in a small group of Chinese patients,
scores of the Simpson Angus Scale, a rating scale for drug-
induced parkinsonism, did not correlate with pharmaco-
kinetic parameters (Chen et al., 2004). Similarly, in a
White sample, no correlation was detected between EPS
and RIS plasma concentrations (Jovanovic et al., 2010);
the over-representation of women in this sample may,
however, limit the validity of the findings; sex and
ancestry have been shown to have a critical influence on
the pharmacokinetics of RIS (Feng et al., 2008).
In contrast, another research group using the Simpson
Angus Scale found consistently higher scores in patients
with higher AM plasma concentrations (Yoshimura et al.,
2001; Kakihara et al., 2005). A positive correlation
between parkinsonian symptoms and plasma concentra-
tions of the AM and the active metabolite was also
detected in a small clinical sample (Spina et al., 2001).
Nevertheless, early findings of the relationship between
exceeding a threshold of dopamine D2-receptor blockade
by antipsychotic treatment and the occurrence of EPS
(Yamada et al., 2002) and the current presented findings
of increased AM concentrations as well as the trend of
higher plasma concentrations of the active metabolite,
9-OH-RIS, in the biperiden group require further clar-
ification. Comparable receptor-binding affinities for D2-
receptors shown by RIS and 9-OH-RIS and higher con-
centrations of 9-OH-RIS and AM in the biperiden group
might explain the occurrence of EPS and the clinical
need for a treatment with the anticholinergic drug
because of clinically apparent side effects. Some phar-
macodynamic differences between RIS and 9-OH-RIS
may offer a plausible explanation; the active metabolite
has a longer half-life time and shows a lower plasma
protein binding than the mother compound (Huang et al.,
1993; Zhou et al., 2006). Furthermore, the formulation
of the two enantiomers (+ )-9-hydroxyRIS and
(− )-9-hydroxyRIS by CYP2D6 and CYP3A4 with dif-
ferent dopamine D2-receptor blocking properties may
contribute toward the interpretation of these data
(Yasui-Furukori et al., 2001).
In sum, our data confirm the essential role of pharma-
cokinetics underlying undesireable clinical side effects,
but still a multidimentional model mediating the sus-
ceptibility to EPS in schizophrenic patients appears to be
more favorable. The data support the recommendation to
measure plasma concentrations in case of side effects
before starting comedication with biperiden (Hiemke
et al., 2011). Using TDM, it can be determined whether
the dose can be reduced without the risk of loss of
therapeutic efficacy.
Table 3 Median dose-adjusted plasma concentrations of
risperidone and 9-hydroxyrisperidone in the study groups without
(R0) and with concomitant biperiden medication (RB)
Group C/D RIS C/D 9-OH-RIS C/D RIS+9-OH-RIS
RB 1.31 (0.11–19.33) 4.69 (0.46–42.00) 6.48 (1.18–44.67)
R0 1.12 (0.02–74.67) 4.33 (0.08–39.30) 6.16 (0.5–88.00)
C/D, dose-adjusted plasma concentrations; RIS, risperidone; 9-OH-RIS,
9-hydroxyrisperidone.
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Comparison of the median plasma concentrations of 9-OH-RIS and
active moiety in the control group (R0, n=772) and the biperiden group
(RB, n=68).*Note the significantly higher plasma concentrations for the
active moiety in the biperiden group (P=0.032). CI, confidence interval;
9-OH-RIS, 9-hydroxyrisperidone.
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Limitations
Our retrospective study of a large group of RIS-treated
patients of naturalistic nature might present some lim-
itations. Therefore, patient information could be con-
sidered less reliable than in the case of a prospective
study. A significant number of clinical parameters
including onset and duration of illness, response scales,
comorbidities, adverse drug-induced reactions, and
duration of previous RIS and biperiden exposure were
not available, and therefore, further analyses could not be
carried out. Furthermore, there might be a large indivi-
dual variation in the sampling time as a result of the
clinical setting, which may have partially accounted for
the pronounced interindividual variation in plasma con-
centrations and metabolic ratios. Detached from con-
sequences of clinical routine, a large interindividual
variability in RIS and 9-OH-RIS concentrations has
already been reported in the literature (Balant-Gorgia
et al., 1999). In the case of multiple plasma concentration
determinations, we minimized the patient bias by
including only one analysis per patient (the most recent
one). To eliminate confounding factors of the pharma-
cokinetic nature of plasma concentration, we excluded
patients under concomitant potent modulators of CYP
activity from the analysis.
Acknowledgements
Conflicts of interest
Ekkehard Haen received speaker’s or consultancy fees
from the following pharmaceutical companies: Servier,
Novartis, and Janssen-Cilag. He is managing director of
AGATE, a non-profit working group to improve drug
safety and efficacy in the treatment of psychiatric dis-
eases. He reports no conflict of interest with this pub-
lication. Christoph Hiemke has received speaker’s or
consultancy fees from the following pharmaceutical
companies: Astra Zeneca, Janssen-Cilag, Pfizer, Lilly and
Servier. He is managing director of the psiac GmbH
which provides an internet based drug–drug interaction
program for psychopharmacotherapy. He reports no
conflict of interest with this publication. Gerhard
Gründer has served as a consultant for Boehringer
Ingelheim (Ingelheim, Germany), Cheplapharm
(Greifswald, Germany), Eli Lilly (Indianapolis, Ind,
USA), Lundbeck (Copenhagen, Denmark), Ono
Pharmaceuticals (Osaka, Japan), Roche (Basel,
Switzerland), Servier (Paris, France), and Takeda (Osaka,
Japan). He has served on the speakers’ bureau of Eli
Lilly, Gedeon Richter (Budapest, Ungarn), Janssen Cilag
(Neuss, Germany), Lundbeck, Roche, Servier, and
Trommsdorf (Aachen, Germany). He has received grant
support from Boehringer Ingelheim and Roche. He is
co-founder of Pharma Image GmbH (Düsseldorf,
Germany) and Brainfoods UG (Selfkant, Germany). He
reports no conflict of interest with this publication.
Georgios Schoretsanitis received grant from the bequest
‘in memory of Maria Zaoussi’, State Scholarships
Foundation, Greece for clinical research in Psychiatry for
the academic year 2015–2016. All other authors declare
there are no conflicts of interest as well. The research
study did not receive funds or support from any source.
References
Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, et al. (2005).
Influence of age and gender on risperidone plasma concentrations.
J Psychopharmacol 19:395–401.
Bader W, Melchner D, Nonenmacher T, Haen E (2005). Determination of five
commonly used antipsychotics in human serum by high performance-liquid
chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry
38:4.
Balant-Gorgia AE, Gex-Fabry M, Genet C, Balant LP (1999). Therapeutic drug
monitoring of risperidone using a new, rapid HPLC method: reappraisal of
interindividual variability factors. Ther Drug Monit 21:105–115.
Caroff SN, Mann SC, Campbell EC, Sullivan KA (2002). Movement disorders
associated with atypical antipsychotic drugs. J Clin Psychiatry 63 (Suppl
4):12–19.
Casey DE (2004). Pathophysiology of antipsychotic drug-induced movement
disorders. J Clin Psychiatry 65 (Suppl 9):25–28.
Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL (2004). Correlation
between scores on continuous performance test and plasma concentration
for schizophrenic patients on risperidone. Psychiatry Clin Neurosci
58:168–172.
Fang J, Bourin M, Baker GB (1999). Metabolism of risperidone to 9-hydro-
xyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn
Schmiedebergs Arch Pharmacol 359:147–151.
Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron
emission tomographic analysis of central D1 and D2 dopamine receptor
occupancy in patients treated with classical neuroleptics and clozapine.
Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544.
Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, et al. (2008).
Population pharmacokinetic analysis for risperidone using highly sparse
sampling measurements from the CATIE study. Br J Clin Pharmacol
66:629–639.
Gebhardt S, Härtling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K,
et al. (2006). Prevalence of movement disorders in adolescent patients with
schizophrenia and in relationship to predominantly atypical antipsychotic
treatment. Eur Child Adolesc Psychiatry 15:371–382.
Ginovart N, Kapur S (2012). Role of dopamine D(2) receptors for antipsychotic
activity. Handb Exp Pharmacol 212:27–52.
Glazer WM (2000). Extrapyramidal side effects, tardive dyskinesia, and the con-
cept of atypicality. J Clin Psychiatry 61 (Suppl 3):16–21.
Grimaldi R, Perucca E, Ruberto G, Gelmi C, Trimarchi F, Hollmann M, Crema A
(1986). Pharmacokinetic and pharmacodynamic studies following the intra-
venous and oral administration of the antiparkinsonian drug biperiden to
normal subjects. Eur J Clin Pharmacol 29:735–737.
Gründer G, Hippius H, Carlsson A (2009). The ‘atypicality’ of antipsychotics: a
concept re-examined and re-defined. Nat Rev Drug Discov 8:197–202.
Haddad PM, Dursun SM (2008). Neurological complications of psychiatric drugs:
clinical features and management. Hum Psychopharmacol 23 (Suppl
1):15–26.
Haen E (2011). Therapeutic drug monitoring in pharmacovigilance and
pharmacotherapy safety. Pharmacopsychiatry 44:254–258.
Hamer S, Haddad PM (2007). Adverse effects of antipsychotics as outcome
measures. Br J Psychiatry Suppl 50:64–70.
Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van
Beijsterveldt L, et al. (1994). The pharmacokinetics of risperidone in humans:
a summary. J Clin Psychiatry 55 (Suppl):13–17.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al.
(2011). AGNP consensus guidelines for therapeutic drug monitoring in psy-
chiatry: update 2011. Pharmacopsychiatry 44:195–235.
Hong KS, Cheong SS, Woo JM, Kim E (1999). Risperidone-induced tardive
dyskinesia. Am J Psychiatry 156:1290.
Huang ML, van Peer A, Woestenborghs R, de Coster R, Heykants J, Jansen AA,
et al. (1993). Pharmacokinetics of the novel antipsychotic agent risperidone
and the prolactin response in healthy subjects. Clin Pharmacol Ther
54:257–268.
ICH expert working group (1996). Harmonised tripartite guideline, validation of
analytical procedures: test and methodology. International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use. Available at: http://www.ich.org/fileadmin/Public_Web_Site/
EPS because of high RIS plasma concentrations? Schoretsanitis et al. 5
Copyright r 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf.
[Accessed 24 April 2016].
Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, et al. (2003). A CYP2D6
phenotype-genotype mismatch in Japanese psychiatric patients.
Pharmacopsychiatry 36:192–196.
Isawa S, Murasaki M, Miura S, Yoshioka M, Uchiumi M, Kumagai Y, et al. (1999).
Pharmacokinetic and pharmacodynamic interactions among haloperidol,
carteolol hydrochloride and biperiden hydrochloride. Nihon Shinkei Seishin
Yakurigaku Zasshi 19:111–118.
Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF
(1988). Pharmacology of risperidone (R 64 766), a new antipsychotic with
serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp
Ther 244:685–693.
Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM (2010). The
role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with
first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol
66:1109–1117.
Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, et al. (2005).
Prediction of response to risperidone treatment with respect to plasma con-
cencentrations of risperidone, catecholamine metabolites, and polymorphism
of cytochrome P450 2D6. Int Clin Psychopharmacol 20:71–78.
Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extra-
pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, ris-
peridone, and sertindole compared to conventional antipsychotics and
placebo. A meta-analysis of randomized controlled trials. Schizophr Res
35:51–68.
Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, Papa P (2001). Long-
term treatment of chronic schizophrenia with risperidone: a study with
plasma levels. Eur Psychiatry 16:57–63.
McEvoy JP (1983). The clinical use of anticholinergic drugs as treatment for
extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol
3:288–302.
Paul L, Musshoff F, Aebi B, Auwärter V, Krämer T, Peters F, et al. (2009).
Guideline of the GTFCh for quality assurance in forensic toxicological
investigations (Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-
toxikologischen Untersuchungen). Toxichem Krimtech 76:142–176.
Regenthal R, Kunstler U, Hesse S, Sabri O, Preiss R (2005). D2 dopamine
receptor occupancy, risperidone plasma level and extrapyramidal motor
symptoms in previously drug-free schizophrenic patients. Int J Clin Pharmacol
Ther 43:370–378.
Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, et al.
(2005). Risperidone plasma levels, clinical response and side-effects. Eur
Arch Psychiatry Clin Neurosci 255:261–268.
Saran BM (1998). Risperidone-induced tardive dyskinesia. J Clin Psychiatry
59:29–30.
Simpson GM, PI EH, Sramek JJ JR (1981). Adverse effects of
antipsychotic agents. Drugs 21:138–151.
Soares KV, Mcgrath JJ (2000). Anticholinergic medication for neuroleptic-induced
tardive dyskinesia. Cochrane Database Syst Rev 2:CD000204.
Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, et al. (2001).
Relationship between plasma risperidone and 9-hydroxyrisperidone con-
centrations and clinical response in patients with schizophrenia.
Psychopharmacology (Berl) 153:238–243.
Spina E, Hiemke C, de Leon J (2016). Assessing drug-drug interactions through
therapeutic drug monitoring when administering oral second-generation
antipsychotics. Expert Opin Drug Metab Toxicol 12:407–422.
Tarsy D (1983). Neuroleptic-induced extrapyramidal reactions: classification,
description, and diagnosis. Clin Neuropharmacol 6 (Suppl 1):S9–S26.
Umbricht D, Kane JM (1996). Medical complications of new antipsychotic drugs.
Schizophr Bull 22:475–483.
US Food and Drug Administration (2001). Guidance for industry on biomedical
method validation. Available at: http://www.fda.gov/ucm/groups/fdagov-pub
lic/@fdagov-drugs-gen/documents/document/ucm070107.pdf. [Accessed
30 March 2016].
US Food and Drug Administration (2014). Drug development and drug interac-
tions: table of substrates, inhibitors and inducer. Available at: http://www.fda.
gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/
DrugInteractionsLabeling/ucm093664.htm. [Accessed 30 September
2015].
Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010). Effect of CYP2D6, CYP3A5,
and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone
and its active moiety. J Clin Pharmacol 50:659–666.
Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, et al. (2002).
Prediction and assessment of extrapyramidal side effects induced by risper-
idone based on dopamine D(2) receptor occupancy. Synapse 46:32–37.
Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G
(2001). Different enantioselective 9-hydroxylation of risperidone by the two
human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268.
Yisak W, Farde L, von Bahr C, Nilsson LB, Fredriksson G, Ogenstad S (1993).
Interaction study between remoxipride and biperiden. Psychopharmacology
(Berl) 111:27–32.
Yoshimura R, Ueda N, Nakamura J (2001). Possible relationship between com-
bined plasma concentrations of risperidone plus 9-hydroxyrisperidone and
extrapyramidal symptoms. Preliminary study. Neuropsychobiology
44:129–133.
Zhou ZL, Li X, Peng HY, Yu XY, Yang M, Su FL, et al. (2006). Multiple dose
pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female
patients with schizophrenia. Acta Pharmacol Sin 27:381–386.
6 International Clinical Psychopharmacology 2016, Vol 00 No 00
Copyright r 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
